C-KJESEidos Therapeutics
genetic disease medicines, TTR stabilization, clinical research
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KJES
C-KJESC-KJESgenetic disease medicines, TTR stabilization, clinical research
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Phase 3 efficacy and safety of acoramidis in subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTR-PN)
This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.
See updated study design under NCT04882735. Phase 3 efficacy and safety of AG10 compared with placebo in subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart failure therapy.
This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Pharmacokinetic) and PD (Pharmacodynamic) of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period.
This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
CURE MUSCULAR DYSTROPHY GROUP OF TN-IN (IND) | 🎧 “We want to help as many patients as possible with new and meaningful medicines.” BridgeBio founder & CEO Neil Kumar joins @ldtimmerman on Th...
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
BBOT Announces Multiple Presentations at the American --> Accessibility: Skip TopNav BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 March 18, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT) TheRas, Inc. (d/b/a BBOT) SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual M
Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update October 29, 2020 | 18 min read Twitter LinkedIn Facebook Email Print Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and prov … nical or other business strategies, and our capital requirements and ability to fund our clinical development plans, are forward-looking statements. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. These forward-looking statements are based on our management’s current beliefs and assumptions about future events and on information currently available to man … lated to: our limited operating history and historical losses, our liquidity to fund the development of acoramidis through current and future milestones, our ability to raise additional funding to complete the development of acoramidis, our dependence on the success of acoramidis, our ability to enroll patients in our ongoing and planned clinical trials, results from our clinical trials and pre-clinical studies and those of third parties working in the same area as … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) September 10, 2024 | 8 min read Twitter LinkedIn Facebook Email Print - Increase in endogenous cortisol production achieved in all patients in higher … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
BridgeBio LLC - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BridgeBio LLC NEWS JOBS IN THE PRESS NEWS Rare diseases FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug The FDA’s priority review acceptance of BridgeBio’s BBP-418 is another step toward what William Blair previously dubbed a “diversified commercial portfolio.” It also adds to the rapidly … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 April 23, 2026 | 4 min read Twitter LinkedIn Facebook Email Print BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (ina … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 April 22, 2026 | 5 min read Twitter LinkedIn Facebook Email Print BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leadin … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor March 9, 2026 | 7 min read Twitter LinkedIn Facebook Email Print BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress May 13, 2026 | 10 min read Twitter LinkedIn Facebook Email Print Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlight … ed in the second half of 2026 across all three programs Cash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress. BBOT's portfolio … xpenses, BBOT’s cash runway and sufficiency of its cash and cash equivalents to fund its operations. These statements are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in dom … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management November 6, 2024 | 4 min read Twitter LinkedIn Facebook Email Print - Case study co-authored by members of BridgeBio senior management and BridgeBio co-founder … l of Portfolio Management. The case study is intended to explore the real-world application of portfolio theory within the biopharmaceutical industry as a unique approach to driving development of innovative therapies, leveraging BridgeBio’s founding and evolution as an example. The case study is featured in the Journal’s 50 th anniversary issue, a special issue celebrating the foundations of modern finance such as Dr. Harry Markowitz’s pioneering work and highlighting the po … ntially more stable return profile and attracting a broader range of investors. Application of this theory furthers a higher volume of early-stage research, which typically comes with higher risk. “BridgeBio was founded at the intersection of a deep interest in portfolio theory and novel genetic medicines for patients in need. The application of portfolio theory, based on Andrew’s insights, is what allowed us to prosecute so many programs for patients that would have otherwis … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Speakers announced for STAT Breakthrough Summit West 2026| STAT Skip to Main Content Donald Trump Eli Lilly Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insurance Hospitals … eck out this year’s lineup below and stay tuned for more announcements to come. Apply to speak today. Sponsor Speaker Aliza Apple, Ph.D. VP of Catalyze360 AI/ML & Global Head of Lilly TuneLab, Eli Lilly and Company Joe Betts-LaCroix CEO, Retro Biosciences Ricky Bloomfield, M.D. Chief Medical Officer, Oura Seemay Chou, Ph.D. CEO, Arcadia Science; President, Astera Institute Sponsor Speaker Jonah Cool, Ph.D. Head of Life Sciences Partnerships & Deployment, Anthropic Spo
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers April 13, 2021 | 5 min read Twitter LinkedIn Facebook Email Print BridgeBio Pharma, Inc. (NASDAQ: BBIO) and The Lundquist Institute for Biomedical Innovation at t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights March 25, 2026 | 11 min read Twitter LinkedIn Facebook Email Print Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to sup … expects that its current cash, cash equivalents and marketable securities will fund operations into 2028 based on its current business plan. License Revenue: No license revenue was recognized for the quarter and year-ended December 31, 2025. License revenue was none and $167.5 million for the quarter and year-ended December 31, 2024, respectively. License revenue recognized in 2024 primarily reflects the receipt of an upfront payment of $150.0 million pursuant to t … nd results of preclinical studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors tha … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactur … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. January 19, 2021 | 9 min read Twitter LinkedIn Facebook Email Print BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos” … ridgeBio stockholders held virtually today, BridgeBio stockholders approved the proposal to issue common stock to Eidos stockholders in connection with the proposed acquisition. “We are ready and eager to welcome Eidos back into BridgeBio’s ecosystem of scientific innovation,” said Neil Kumar, Ph.D., founder and CEO of BridgeBio and CEO of Eidos. “We believe this merger will allow us to fully unlock the potential of acoramidis, the investigational therapy Eidos is developing … wned by BridgeBio or any of its subsidiaries and that is not a restricted share award, either (1) 1.85 shares of common stock of BridgeBio (the “Stock Consideration”) or (2) $73.26 in cash (the “Cash Consideration” and, together with the Stock Consideration, the “Merger Consideration”), subject to proration. The Cash Consideration will be prorated as necessary to ensure that the aggregate amount of cash consideration payable in the merger is no greater than $175 million. Any … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect inn
Eidos Therapeutics Closes on Series B Round Worth $64M - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases A … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Eidos Therapeutics Closes on Series B Round Worth $64M April 5, 2018 | 2 min read | Mark Terry Twitter LinkedIn Facebook Email Print Eidos Therapeutics closed on a $64 million Series B financing round. The funds will be used to advance the company’s product candidate, AG10, into … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Can … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. January 26, 2021 | 9 min read Twitter LinkedIn Facebook Email Print BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Ei … ned by BridgeBio or any of its subsidiaries and that was not a restricted share award, either (i) 1.85 shares of BridgeBio common stock or (ii) if an election to receive cash was properly made prior to 5:00 P.M., New York City time, on January 21, 2021, $73.26 in cash. Eidos stockholders should contact American Stock Transfer & Trust Company, LLC, the exchange agent for the transaction, by calling toll-free at (877) 248-6417 or at (718) 921-8317, if they have any question … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types June 12, 2025 | 4 min read Twitter LinkedIn Facebook Email Print - Data show that BBO-10203 covalently and specifically … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Dru … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types November 19, 2021 | 10 min read Twitter LinkedIn Facebook Email Print BridgeBio Pharma, Inc. announced they have entered into a strategic coll … olangiocarcinoma (CCA) with a FGFR2 fusion or other rearrangement. Helsinn will fund the majority of ongoing and future research and development related to infigratinib in oncology in the foregoing territory. BridgeBio will be eligible for tiered royalties as a percentage of adjusted net sales, and potential payments totaling up to $2.45 billion USD in the aggregate. BridgeBio previously entered a strategic collaboration with LianBio for development and commercialization of i … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIB … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib) October 11, 2022 | 10 min read Twitter LinkedIn Facebook Email Print BridgeBio Pharma, Inc., (Na … luding the potential availability of initial data at the end of 2024, the FDA’s grant of Fast Track designation for the investigation of BBP-398 in combination with LUMAKRAS for adult patients with previously treated, KRAS G12C-mutated, metastatic NSCL, the ability of combining SHP2 inhibition with KRAS G12C inhibition in patients with the KRAS G12C mutation to prevent oncogenesis and overactive cellular proliferation, the availability of initial Phase 1 da … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell an … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases December 23, 2020 | 5 min read Twitter LinkedIn Facebook Email Print UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement o … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Another Biotech is Born as Bay Area's BridgeBio Pharma Launches Eidos Therapeutics With $27 Million - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Another Biotech is Born as Bay Area’s BridgeBio Pharma Launches Eidos Therapeutics With $27 Million April 27, 2017 | 2 min read Twitter LinkedIn Facebook Email Print April 27, 2017 By Mark Terry , BioSpace.com Breaking News Staff Palo Alto, Calif,-based BridgeBio Pharma announced that it has … or liquidity in ways that are unique as compared with the traditional c-corp or fund structures seen in this industry.” Since 2016, BridgeBio deployed over $50 million in R&D commitments. Twitter LinkedIn Facebook Email Print Startups NextGen: Class of 2026 BridgeBio LLC LATEST Duchenne muscular dystrophy Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy June 26, 2026 · 4 min read · Heather McKenzie Layoff … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition August 12, 2025 | 10 min read Twitter LinkedIn Facebook Email Print Business combination transaction with Helix Acquisition Corp. II, a special purpose acqui … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology ProgramsDr. Wallace brings over two decades of experience in oncology drug discovery to leadership team - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology ProgramsDr. Wallace brings over two decades of experience in oncology drug discovery to leadership team December 9, 2019 | 3 min read Twitter LinkedIn Facebook Email Print BridgeBio Pharma, Inc. … alented BridgeBio team,” Dr. Wallace said. “BridgeBio is the perfect setting to apply my experience in small molecule drug discovery to challenging targets that will provide new, meaningful therapeutics to patients afflicted with cancer. When I saw the targets and the promising chemistry underpinning the company’s oncology programs, I knew this was where I wanted to be.” About BridgeBio Pharma BridgeBio is a team of experienced drug discoverers, developers, and innovators wor … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
BridgeBio and Amgen Unite on Combination Therapy for Advanced Solid Tumors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opini … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business BridgeBio and Amgen Unite on Combination Therapy for Advanced Solid Tumors January 13, 2022 | 2 min read | Mark Terry Twitter LinkedIn Facebook Email Print Michael Vi/Shutterstock BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Bay Area's BridgeBio Pharma Comes Out of Stealth Mode - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Bay Area’s BridgeBio Pharma Comes Out of Stealth Mode January 4, 2017 | 2 min read Twitter LinkedIn Facebook Email Print BridgeBio Pharma Launches With A Focus On Precision Medicines For Genetic Diseases PALO ALTO, Calif.--( BUSINESS WIRE )--California-based BridgeBio Pharma has come out of s … or liquidity in ways that are unique as compared with the traditional c-corp or fund structures seen in this industry.” BridgeBio has seven programs to date, with two in the clinic and hopes to add to its diversified portfolio of assets based on a systematic mapping of the genetic disease landscape. It has deployed over $50 M in R&D commitments in 2016. Twitter LinkedIn Facebook Email Print Startups BridgeBio LLC LATEST Duchenne muscular dystrophy Capricor thrown for anot … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
Readout LOUD podcast: BridgeBio's great week, Moderna's fall Skip to Main Content Manage alerts for this article Email this article Share this article Eli Lilly Donald Trump Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & I … ver you get your podcasts. Advertisement biotechnology , Moderna , Novo Nordisk Submit a correction request Reprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter , and co-hosts STAT’s weekly biotech podcast, The Readout Loud . You can reach Elaine on Signal at elaine
A breakup strategy that’s inspiring clinical candidates for cancer --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section How biochemistry fuels World Cup athletes Meet Jasmine Clark, the self-described ‘mad scientist’ running for the US House Australia’s $1.4 billion PFAS lawsuit could be a global model The road to sustainable rare earth … a Senior Correspondent for C&EN based in Boston. Send the reporter feedback Submit a Letter to the Editor for publication Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society Enjoyed the article? Share A breakup strategy that’s inspiring clinical candidates for cancer Scientists seek molecules that will disrupt the Ras-PI3Kα interaction cen.acs.org ADVERTISEMENT More in Cancer Editor's Picks Popular Return to top 2/3 FREE ARTICLES LEFT
Interview with Neil Kumar, CEO of BridgeBio on biotech innovation | Jean-François Tamby, MD-MBA posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … eed them most. 🧬💊 It’s a call to action for scientists: stay adaptable, think application, and keep your compass set on patient impact. 🎥 Watch the reel and tell us-what skill are you learning next? Watch full Podcast in Youtube: https://lnkd.in/dxm5Umhh #PharmaInnovation #DrugDiscovery #Biopharma #TranslationalResearch #LifeSciences #BiotechLeadership #ResearchMindset #FutureOfMedicine #PharmaNow …more 45 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or ad
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
A Contrarian Mindset: Neil Kumar, Co-Founder & CEO of BridgeBio Trium Perspectives Subscribe Sign in Podcast A Contrarian Mindset: Neil Kumar, Co-Founder & CEO of BridgeBio The One of One Podcast, hosted by Darren Gold. The Trium Group May 29, 2025 1 Share Listen Here In this episode of One of One, Darren sits down with Neil Kumar, co-founder and CEO of BridgeBio, a leading biotech company focused on treating rare genetic conditions that largely affect children. Neil is a deeply contrarian thinker and leader. It shows up in his decision to start a company ten years ago focused on a mar … ture that gets in early and tries to IPO or sell something. It could be a hedge fund investor that gets in as the thing, IPOs along the middle ground. But there are very few people who are focused on the NPV of the asset, like the overall economic value and what it could do, especially in these small markets. So that was the first thing that we thought of is like, look, there may be stuff that we’re working on that is never popular for big pharma. And you know, our proposal i … never popular for big pharma. And you know, our proposal is not to sell it. Our proposal is to build a generational business, but it’s going to take some time for us to do it. So that’s, that’s one set of contrarian beliefs that has to do with what, what is the fundamental value of a program. Another set of contrarian beliefs has to do with how do you organize? You know, we, we have a concept of a minimum viable team, minimum viable process. We have to do that because the mar … es and values are and then react to an ever changing playing field by trying to apply it in the best and most opportunistic way. And I see science as that. I mean I don’t wake up tomorrow and say I’m only going to work on this type of therapeutic area. I’m only going to work with this type of modality. I try to stay responsive to whatever opportunities come about that helped me to help as many patients as possible. So those are the books that I. That I think about a lot, at l … n 20 years later I attended one of his lectures and said, hey, we should try to apply some of your principles to starting a biotechnology firm. And likewise, my mentors from 3rd Rock are all co founders with me here and I continue to work with them. My graduate advisor, his input it in a lot of different ways to some of the science that we do, an
A Contrarian Mindset: Neil Kum… - One of One - Apple Podcasts Search Home New Top Charts Search May 29, 2025 44 min A Contrarian Mindset: Neil Kumar, Co-Founder & CEO of BridgeBio One of One Play In this episode of One of One, Darren sits down with Neil Kumar, co-founder and CEO of BridgeBio, a leading biotech company focused on treating rare genetic conditions that largely affect children. Neil is a deeply contrarian thinker and leader. It shows up in his decision to start a company ten years ago focused on a market that most others ignored, in the unique hub and spoke organizational stru
BridgeBio spinout launches with $200M for KRAS cancer drugs | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore … nth. It has company, however. Frontier Medicines recently raised $80 million to fund, in part, development of a drug that also targets the on and off states of the KRAS protein. BridgeBio Oncology Therapeutics has another KRAS inhibitor, one designed to bind to several different mutated types of KRAS protein, that’s earlier in development. The company plans to ask early next year for regulatory clearance to begin testing. Also in its pipeline is another kind of cancer drug. C
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
BridgeBio Empleos y Vacantes (7 abiertas) · $180K-$220K · Postula… Growth . Talent Empleos Resources Empresas Integrations Agents New Docs Search jobs, companies, roles... ⌘K Search ⌘K 🌎 LatAm Iniciar sesión Publicar empleo Patients first, metrics seco From lab to living rooms. CAN YOU MOVE RARE DISEASE? BridgeBio Commercial-stage biotech scaling marketing for genetic disease and cancer treatments. Early-stage USA Commercial stage Biopharma USA-focused Marketing-heavy hiring Patient-centric Famous for What BridgeBio is known for AG10 oral small molecule in development for genetic disease trea … disease awareness, HCP outreach, and patient community strategy. If you want to apply growth principles to healthcare outcomes rat About In their own words BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule. Open positions Posiciones abiertas … re remote or hybrid. Filter by location on each listing for specifics. How do I apply to BridgeBio? Click any open role on this page to view the listing and apply directly. Growth.Talent forwards applications to the recruiter's inbox or to BridgeBio's ATS. No intermediary, no resume gate. Are you BridgeBio ? Claim this page and turn it into a banger. You control the cover image, the team photos, the testimonials, the open roles you want to push. Free to claim. We ve
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
BBOT registers 63,054,549 shares; new CEO named | BBOT Prospectus Summary --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … ive Director of Oncology Research. He has led multiple Investigational New Drug application submissions, authored more than 50 peer-reviewed articles, presented at numerous national and international scientific conferences, and holds diverse patents for the treatment of malignant diseases. Dr. Beltran completed postdoctoral work in Molecular and Cellular Pharmacology at the University of Miami, holds a Ph.D. in Cancer Biology from the University of Texas, MD Anderson Can
BRIDGEBIO SERVICES INC H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support BRIDGEBIO SERVICES INC H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 3 Total Filings 2021-Present 66.7% Ap … Most Recent) Role Last Filing Total (2021–Present) Amyloidos Scientific Fellow (Fellowship) Jan 12, 2024 1 Senior Associate Scientist Jun 1, 2022 1 VP Business Development & Operations and Head of China Mar 29, 2021 1 Top Roles by Filings Role Count Median Salary Min Max Amyloidos Scientific Fellow (Fellowship) 1 $325,000 $325,000 $325,000 Senior Associate Scientist 1 $115,000 $115,000 $115,000 VP Business Development & Operations and Head of China 1 $252,000 $252,000
Women As One and BridgeBio Join Forces to Tackle Gender Disparities in Cardiology - Women As One Skip to content Home For Physicians For Physicians Sign up for The Pulse to join our community of talented women healthcare professionals and further your professional development, all while engaging in tailored programs led by thought leaders in the industry. View opportunities Awards CLIMB RISE Resources Join us Log in to The Pulse For Partners For Partners At Women As One, we’re committed to shaping the future careers of women in medicine. We believe that creating more opportunities for women ca … aScript in your browser to complete this form. First Name * Last Name * Email * Submit © Copyright 2024. Women As One. All Rights Reserved Cookie Policy Terms and Conditions Privacy Policy Site designed and developed by Cornerstone DM
We are excited to recognize... - NBIA Disorders Association Facebook Log In NBIA Disorders Association's Post
GSA eLibrary Contractor Information An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search: | all the words any of the words exact phrase (Vendors) How to change your company information System Notice: eLibrary is experiencing an issue with MAS 8(a) Po
BridgeBio Pharma Regulatory Milestones - GlobalData Visit Corporate Site Sign in Search Menu Sign In Who We Are Who We Are Your powerful market insights platform. Book a demo Mission & Values Clients Media People Why GlobalData Resource Center CSR Partners Careers History Investors Industries We Cover Industries We Cover Your curated industry news round-up. Subscribe now Aerospace, Defense & Security Agribusiness Apparel Automotive Banking & Payments Construction Consumer Foodservice Healthcare Insurance Medical Devices Mining Oil & Gas Packaging Pharmaceutical Power Public Sec
Bridgebio QED - Pediatric Endocrine Society Skip to content Menu Clinical Resources Clinical Resource Library Referral Guidelines New Meds & Tech Drug Shortages Drug Alerts & Recalls Special Interest Groups Online Community Insurance Appeal Letter Templates And the survey says… Patient Resources What is a Pediatric Endocrinologist? Patient Education Patient Education Videos Find a Pediatric Endocrinologist Camps Clinical Studies Transition Toolkit Professional Links Education & Events Events Calendar PES Annual Meeting Future Meetings Board Review Course Online Education PES Lea
BridgeBio Pharma, Inc. (Form: S-1, Received: 05/24/2019 16:48:20) Table of Contents As filed with the Securities and Exchange Commission on May 24, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 84-1850815 (State or Other Jurisdi … in clinical trials that, if positive, we believe could support the filing of an application for marketing authorization. Two of these product candidates are in Phase 3 clinical trials, one is in a Phase 2/3 clinical trial, and one is in a Phase 2 clinical trial. We focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. Our approach is to translate research pioneered at academic laboratories and leading medi … e are best suited to continue a program’s development, we will continue to fund it internally. If we believe a strategic partner is better suited to progress a program, we will consider externalizing development at economically attractive terms. Our Pipeline Our product platform supports the advancement of our current pipeline, which can be divided into three key categories: • Mendelian : Ten small molecule and protein replacement product candid … the treatment of FGFR-driven cancers and achondroplasia, for which we intend to submit an NDA in 2020 for the treatment of cholangiocarcinoma as a second-line or later therapy. • BBP-631 (under development at our subsidiary, Adrenas Therapeutics, Inc.), an AAV5 gene transfer product candidate in preclinical development for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. • &nbs … the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an em
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BridgeBio Pharma Inc. - leading independent proxy advisory firm iss recommends bridgebio pharma and eidos therapeutics stockholders vote “for” proposed merger Skip to main content Overview Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents State Disclosures Board of Directors Committee Composition Resources Investor Email Alerts Contact Us News Details View All News leading independent proxy advisory firm iss recommends bridgebio pharma and eidos therapeutics stockholders vote “for” … of directors unanimously recommends that BridgeBio stockholders vote “FOR” the proposal to approve the issuance of BridgeBio shares in connection with the merger agreement. In light of the fact that BridgeBio owns a majority of the issued and outstanding Eidos common stock and certain BridgeBio officers and directors also serve on the Eidos board, the Eidos board formed a special committee of independent directors (the “Eidos special committee”) to consider and negotiate the … . The Eidos special committee recommends that Eidos stockholders vote “FOR” the proposal to approve the merger with BridgeBio as well as additional proposals to be considered at the Eidos special meeting. The merger is expected to be consummated by the end of the first calendar quarter of 2021, subject to the receipt of the required approvals from both BridgeBio and Eidos stockholders and other customary closing conditions. Following the consummation of the merger, Eidos will
%PDF-1.3 %��������� 3 0 obj > stream x�W�r�4}�Wt��Ɏbɺ��Ol�T���5�-� ���V��2fv ��-�ӧ[�zC�)'3� ����� o�G��n�~��{"[��v�.�=� �L� Y L ��l���6�h�q��� �D��G �S���k�q��c��H�ߙ������R�myX0A`��JO�' � ���ex � � %�@g�/0fb�`����[4!� /d ���Ʉ8�0�ܣ���ec^̃����9����~����v�[XG� ��EV�0��� �p I��#�$x0!!�*�{%+�TΊʽ��P��-� ����� ��ˀ E��[�����*��Tj V�6��^ ���:��(d8'���X�`�8��� �EDϢ����%䫨���%�@�m�� ���q���ӀP�7)i��9@�pZm����F%�)�F�[�)Q� /R�Q.H#P��i{ri$2�;ѬC���q1x���;����y��9zˌ�5��ٴ�2�z?��^8��b��� ��0 !P�;� ��k|�C��k�J%um�h�R�MV�kրb�l!��N ������F_�(�n�� ܽ�
BridgeBio Oncology names Pedro Beltran as CEO | BBOT 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas … ive Director of Oncology Research. He has led multiple Investigational New Drug application submissions, authored more than 50 peer-reviewed articles, presented at numerous national and international scientific conferences, and holds diverse patents for the treatment of malignant diseases. Dr. Beltran completed postdoctoral work in Molecular and Cellular Pharmacology at the University of Miami, holds a Ph.D. in Cancer Biology from the University of Texas, MD Anderson Can
Pedro J. Beltran, PhD | BridgeBio Oncology Therapeutics About Pipeline Publications Investors Careers Contact Us Menu Menu Pedro J. Beltran, PhD Chief Executive Officer Pedro joined BridgeBio Pharma in 2020 as Senior Vice President of Biology and became Chief Executive Officer of BBOT in 2026. Prior to BridgeBio, Pedro was Senior Vice President, Head of Biology at UNITY Biotechnology and Executive Director, Oncology Research at Amgen, Inc. Pedro has led multiple IND filings, authored more than 50 peer-reviewed articles, presented at multiple national/international scientific conferences, and h
Research Grants & Funding Opportunities - BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM? Present … mia type 1 (ADH1) Degenerative cerebral disease Canavan disease Key Information RFP: Educational Topic: Implementation of Artificial Intelligence (AI) in Cardiovascular Care PDF RFP: BridgeBio ATTR-CM Fellowship Grant PDF We accept applications from a wide range of healthcare organizations, associations, medical specialty societies, academic institutions, hospitals, and medical education companies. Third Parties If a third-party provider will be utilized to implement a propos … hird Parties If a third-party provider will be utilized to implement a proposed grant project or program, the provider must not be owned in whole or in part by, or controlled by: A practicing physician or other HCP A group practice of physicians or other HCPs An individual who is an immediate family member of a practicing physician or other HCP Other key parameters: Funding from other pharmaceutical/biotechnology companies, in addition to BridgeBio, is preferred (eg, multiple … rom BridgeBio Funding is permitted only to legally established organizations; a grant cannot be provided to an individual Requesting organization and grant request must be in full compliance with all regional and local codes, laws, and industry regulations, including, but not limited to, anti-corruption, transparency, and privacy laws and regulations Introducing BridgeBio Insights Explore videos, white papers, resources and opinions focused on our goal of better serving patie
Eidos Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment … io Pharma, Inc. And Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline For Merger GlobeNewswire • Jan 14, 2021 • BridgeBio , Eidos Therapeutics • WeissLaw LLP Reminds MTSC, EIDX, IPHI, and ALXN Shareholders About Its Ongoing Investigations PR Newswire • Dec 30, 2020 • Weisslawllp , MTS Systems , Eidos Therapeutics , Inphi and 1 other • Halper Sadeh LLP Investigates the Following Companies - PRGX, STND, NK, EIDX, ARA PR Newswire • Dec 28, 2020 • Halper Sadeh
EX-10.5 5 bbio-ex10_5.htm EX-10.5 EX-10.5 Exhibit 10.5     CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.             EXCLUSIVE LICENSE AGREEMENT by and among Eidos Therapeutics, Inc., BridgeBio International GmbH, BridgeBio Europe B.V., and Bayer Consumer Care AG entered into as of March 1 st , 2024               TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 … Bayer 28 7.2 Eidos Retained Rights; License to Eidos 28 7.3 Sublicensing 29 7.4 Grant of License to Licensed Product Trademark. 30 7.5 [***] 31 7.6 Negative Covenant 31 7.7 No Implied Licenses 31 7.8 New Know-How and Patent Rights relating to Licensed Product 31 7.9 Eidos In-License Agreements 31 7.10 Technology Transfer 32 7.11 Exclusivity 33 Article 8 FINANCIALS 34 8.1 Upfront Payment 34 8.2 Development and Regulatory Milestone Payments 34 8.3 Sales Milestone Payments 35 8. … E RESOLUTION 63 14.1 Disputes 63 14.2 Arbitration 63 14.3 Governing Law 64 14.4 Award 64 14.5 Injunctive Relief; Remedy for Breach of Exclusivity 64 14.6 Confidentiality 64 14.7 Survivability 65 14.8 Jurisdiction 65 14.9 Patent and Trademark Disputes 65 Article 15 MISCELLANEOUS 65 15.1 Entire Agreement; Amendment 65 15.2 Force Majeure 65 15.3 Notices 66 15.4 Joint Liability of Eidos 66 15.5 No Strict Construction; Headings 66 15.6 Assignment 66 15.7 Further Actions 68 15.8 Co … ith respect to Patents or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patents or Know-How, and (b) with respect to proprietary materials, including Regulatory Materials, Regulatory Approvals or the Compound, the possession by a Party of the ability to supply such item to the other Party as provided herein, in each case of (a) and (b) without violating the terms of any agreement or arrangement between such Party and any other par … ection 1.54, such Effective Date shall remain unaffected and Section 10.7 shall apply. 1.55 “ Eidos ” has the meaning set forth in the preamble to this Agreement. 1.56 “ Eidos Claims ” has the meaning set forth in Section 11.2. 1.57 “ Eidos In-License Agreement ” has the meaning set forth in Section 7.9.
Neil Kumar - IIT Bay Area Home About Us Programs Startup Showcase Women Leadership Reconnect Alumni Past Conferences Contact Us Register Home About Us Programs Startup Showcase Women Leadership Reconnect Alumni Past Conferences Contact Us Close Event description put here @my_event_day Event Details Sunday, 05 November 2022 2:00 PM – 3:30PM Mas Montagnette 198 West 21th Street, NY +1 485-048-1995 View Map Facebook Twitter Pinterest Instagram Neil Kumar IIT Bay Area > Speakers > Neil Kumar Designation: CEO, BridgeBio Pharma © All Rights Reserved by iitbayconf.org
--> Organization | Eidos Therapeutics, Inc. --> Open Menu Center for Research Innovation in Biotechnology (CRIB) College of Pharmacy in collaboration with --> Clinical Drug Experience Knowledgebase Back Close Menu Drugs Drugs Search by Name FDA Approval Trends Advanced Search FDA Approved Drugs Orgs Orgs Search by Name Organization Trends Advanced Search Indications Indications Search by Name Mechanisms Mechanisms Trials Trials FDA Approvals FDA Approvals About CDEK About CDEK Glossary Advanced Search Guide Search by Name More --> Eidos Therapeutics, I
BridgeBio Pharma, Inc. (Form: 10-Q, Received: 08/05/2025 16:58:11) 0001743881falseQ2--12-31http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAs … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth companyR … nd (v) recognize revenue when (or as) we satisfy our performance obligation. We apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services we transfer to the customer. At inception of the arrangement, we assess the promised goods or services to identify the performance obligations within the contract. We then recognize as revenue the amount of the transaction price that is al … and regulatory success. • License fees : For arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront licen … nts with certain employees and consultants as part of the 2020 Stock and Equity Award Exchange Program (the “Exchange Program”, refer to Note 15). The compensation arrangements under the Exchange Program are to be settled in the form of equity only. Performance-based milestone awards that are settled in the form of equity are satisfie
S-1 1 d613995ds1.htm S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on May 24, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIDGEBIO PHARMA, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 84-1850815 (State or Other Jurisdiction of Incorporation or Organizatio … in clinical trials that, if positive, we believe could support the filing of an application for marketing authorization. Two of these product candidates are in Phase 3 clinical trials, one is in a Phase 2/3 clinical trial, and one is in a Phase 2 clinical trial. We focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology. Our approach is to translate research pioneered at academic laboratories and leading medi … e are best suited to continue a program’s development, we will continue to fund it internally. If we believe a strategic partner is better suited to progress a program, we will consider externalizing development at economically attractive terms. Our Pipeline Our product platform supports the advancement of our current pipeline, which can be divided into three key categories: • Mendelian : Ten small molecule and protein replacement product candid … the treatment of FGFR-driven cancers and achondroplasia, for which we intend to submit an NDA in 2020 for the treatment of cholangiocarcinoma as a second-line or later therapy. • BBP-631 (under development at our subsidiary, Adrenas Therapeutics, Inc.), an AAV5 gene transfer product candidate in preclinical development for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. • &nbs … the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an em
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BridgeBio | Biotechnology | The Pharmaletter Saturday 27 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene
--> BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances top of page Home Quick Takes Around Kendall Science Spotlight BiotechTV U Company News Bright Minds Shows Biotech Direct BioVenture VoiCes Biotech CEO Sisterhood The Studio at Kendall Square Off-Target Effects with Matt Gline Tech + Tours BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances Nov 21, 2023 1 min read Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 that will read in ADH1 early next year, and the draw to invest in
BridgeBio Pharma Inc. - bridgebio pharma’s qed therapeutics presents data on infigratinib in cholangiocarcinoma and urothelial carcinoma at the american society of clinical oncology 2020 virtual scientific program Skip to main content Overview Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents State Disclosures Board of Directors Committee Composition Resources Investor Email Alerts Contact Us News Details View All News bridgebio pharma’s qed therapeutics presents data on infigratinib in c … nd advanced urothelial carcinoma with FGFR3 genomic alterations. QED intends to submit a New Drug Application (NDA) with the United States Food and Drug Administration for second and later-line cholangiocarcinoma in 2020. QED Therapeutics is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to conduct further clinical trials to evaluate the potential for infigratinib to treat patients with other FGFR-driven tumor types and rare d … eutics’ regulatory approval process, the timing of the submission of a New Drug Application (NDA) for second- and later-line cholangiocarcinoma, clinical trial designs, including the design of the ongoing, placebo-controlled PROOF 302 study, clinical development plans, clinical trial results, timing and completion of clinical trials, clinical and therapeutic potential of infigratinib, including for patients whose tumors progress after second-line chemotherapy, reflect our cur
BridgeBio Oncology Therapeutics Announces Poster Presentations at 2025 AACR-NCI-EORTC Conference | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On BBOT Stock Enter your email to receive free breaking news alerts and insights related to BBOT. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Election Fundraising Insider Tra
36F79725D020E | Veterans Affairs Award | INTERIM AGREEMENT UNDER FSS SCHEDULE 65 I B DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS Solutions × Solutions for Federal Contractors End-to-end platform for contractors and teams Opportunity Sourcing Pipeline Management CRM for GovCon Task Order Management Business Process Automation Market Intelligence Teaming & Partner Management State & Local Opportunities Wayfinder AI for GovCon Solutions for Federal Consultants Collaboration tools to engage with clients Resources About Blog Sign in Contact Sales Resources Ab … 5D020E - INTERIM AGREEMENT UNDER FSS SCHEDULE 65 I B DRUGS,... Federal Contract Award Search » FSS Award This FSS contract was awarded in FY2025 on Jan 23, 2025 to BRIDGEBIO PHARMA, INC. by National Acquisition Center. There have been no obligations to date with a ceiling value of $25k, showing a ~0% burn rate so far on the contract. The contract was not competed under any preference program with 999 offers received. We expect a 6 year duration with ultimate completion d … acquisition entity within the Federal Government, manages a catalog of Multiple Award Schedules (MAS). The GSA uses MAS to establish lines of business or cohorts of contractors grouped by similar goods and services. Schedules are open to all government customers and provide a streamlined process to procure various professional services, IT services, and products, ranging from cars to hardware. Read the full report Contract Number 36F79725D020E Contractor BRIDGEBIO PHARMA, INC … Contractor BRIDGEBIO PHARMA, INC. Obligations to Date $0.00 Ceiling Value $25k Award Date 01/23/2025 Contract Type FSS Competition Set Aside Type No set aside used Buying Agency/Office Veterans Affairs » VA Office of Acquisition, Logistics and Construction » Office of Procurement, Acquisition and Logistics » National Acquisition Center Read the full report Win More Federal Business Imagine a world where every report, every insight is tailored specifically t … o every pursuit. Every opportunity, every report, tailored specifically to you. Award Research & Market Intelligence Find gaps in the market, identify key competitors and teaming partners, evaluate performance, and analyze pathways to new business. Start Your Free Account Today That's right. It's free to get started with Federal Compass Gain Full
Bridgebio Pharma (LSA5MDHDB961) --> --> Sign In Tools to Win. Insights to Lead. Powerful Market Intelligence Leading Business Development Tools Authoritative Capital Markets Let's keep this going You've used all of your free views Free Trial Schedule Demo Free Trial Schedule Demo Description Search HigherGov Federal State | Local EXPLORE Search All BUSINESS DEVELOPMENT Opportunities Contracts Grants Pursuit Management Pipelines   +   Pursuits   +   Activities   +   Partner Finder Government Buyers Labor Pricing MARKET INTELLIGENCE Analysis Awards Vehicles Contract … nts Awardees Government Agencies People Documents Reference Programs Defense IT Grant SEWP Classifications NAICS NIA NSN PSC DoD Budget Protests Capital Markets M&A Transactions Investors Advisors TOOLS Downloads Favorites Saved Searches FOIA News+ Help Docs Federal State | Local BUSINESS DEVELOPMENT Opportunities Contracts Pursuit Management Pipelines   +   Pursuits   +   Activities   +   Government Buyers Labor Pricing MARKET INTELLIGENC … s Favorites FOIA Saved Searches Help Docs More SOLUTIONS FOR Contractors Grant Recipients Consultants Investors and Banks Government Agencies FEATURES Market Intelligence CRM Capital Markets Big Data & AI LEARN MORE Pricing Plans Demo Sign In Free Trial Notify New Contract Awards New Grant Awards Favorite Export Toggle Dropdown CSV Excel Claim Share Toggle Dropdown Copy URL Email Tweet Search Awardees Bridgebio Pharma UEI: LSA5MDHDB961 • CAGE: 8FVJ9 Overview Anal … pboard CSV Excel All Records CSV Excel Contract Vehicles Bridgebio Pharma multi-award contract vehicles Explore Export Visible Records Clipboard CSV Excel All Records CSV Excel IDV Awards Bridgebio Pharma indefinite delivery vehicle awards Additional Analysis Market Size Analysis Active Federal Opportunities for Registered NAICS About Contact Terms Privacy © 2026 HigherGov
#heartfailure26 | BridgeBio LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip
Karteek Sandadi - Senior Director, Global Regulatory Operations at BridgeBio | The Org Platform Enrich Pricing Log in Sign up BridgeBio Karteek Sandadi Unverified Karteek Sandadi Senior Director, Global Regulatory Operations Contact Karteek Sandadi is an experienced professional in the field of regulatory services and consulting, currently serving as Practice Manager for R&D Services at Veeva Systems since February 2018, where previous roles included Team Lead and Senior Consultant in the same division. Prior to Veeva Systems, Karteek held several senior positions at EXTEDO from May 2012
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BridgeBio Momentum at JPM Healthcare Conference | BridgeBio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … this comment Bravo Neil Kumar , at CURE SYNGAP1, 501(c)(3) FKA SynGAP Research Fund (SRF) we are hopeful your #SYNGAP1 program is just as successful. Like Reply 2 Reactions 3 Reactions See more comments To view or add a comment, sign in More Relevant Posts Precigen 9,336 followers 5mo Report this post At the 2026 JP Morgan Healthcare Conference, Helen Sabzevari , PhD, President and CEO of #Precigen , shared how 2025 marked a transformational year for the company an
BridgeBio Pharma Inc. - BridgeBio to Participate in the J.P. Morgan Healthcare Conference Skip to main content Overview Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents State Disclosures Board of Directors Committee Composition Resources Investor Email Alerts Contact Us News Details View All News BridgeBio to Participate in the J.P. Morgan Healthcare Conference January 5, 2026 Download (opens in new window) PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BB
Excited to share that Unnatural Products Inc., a portfolio company, has secured another major win in AI-driven macrocyclic drug discovery! Palo Alto-based biotech company BridgeBio Pharma (BBIO… | Garri Zmudze LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any t … tations to Health - and its groundbreaking GigaAssay™ platform, Altagenics will apply next-generation functional genomics to map protein function at unprecedented scale—unlocking novel therapeutic targets and accelerating the development of first-in-class therapies. This launch marks a major step in GLD’s strategy to build platform-driven companies capable of reshaping drug discovery economics and outcomes. Learn more here: https://lnkd.in/eB6pu2mh #BiotechInnovation #DrugDis
BridgeBio Pharma, Inc. - AnnualReports.com Menu BROWSE BY Exchanges Industry Other Filters BROWSE BY Exchanges Industry Other Filters 0 BridgeBio Pharma, Inc. Ticker BBIO Exchange NASDAQ More Industry Biotechnology More Sector Healthcare More 201-500 Employees Based in Palo Alto, California BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian
Foresite Capital --> --> Eidos Therapeutics, Inc. (Alumni) – Foresite Capital Strategy Portfolio People Careers News Blog Contact Us --> Back Portfolio Next Eidos Therapeutics is a biopharmaceutical company that focuses on developing genetically targeted therapies for treating transthyretin amyloidosis (ATTR), a group of diseases caused by a protein misfolding disorder. They were acquired by BridgeBio Pharma in 2020. Back Portfolio Next ©2026 Foresite Capital Management, LLC. Site by GOODLAB Strategy Portfolio People Careers News Blog Contact Us Contact Us Foresite Labs Investor Login Te
BridgeBio and Resilience Announce Strategic Multi-Year Partnership Skip to main content Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy NEWS EVENTS CAREERS OFFERINGS Trusted, Vetted, and Ready to Roll. Named solutions for critical biomanufacturing needs—each powered by the full strength, speed, and science of Resilience. Sprout Solutions™ For your next step in Drug Substance or Fill/Finish, Sprout nurtures your molecule with transpare
MedEdge MEA - BridgeBio Oncology Therapeutics, Inc. (BBOT)... Facebook Log In MedEdge MEA's Post MedEdge MEA April 23 · Shared with Public BridgeBio Oncology Therapeutics, Inc. (BBOT) has appointed Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman as the company enters its next phase of growth. These strategic leadership appointments come as BBOT advances its oncology pipeline across multiple RAS-driven cancers. #BBOT #BridgeBio #Leadership #CEO #COO #ExecutiveChairman #BusinessGrowth #CorporateNews #Med
Helix Acquisition Corp. II has agreed to merge with BridgeBio Oncology Therapeutics - Lincoln International LLC Skip to main content Who We Are About Lincoln International About MarshBerry Firm Leadership Our People By Service Mergers & Acquisitions Capital Advisory Private Funds Advisory Valuations & Opinions By Industry Business Services Consumer Energy Transition, Power & Infrastructure Financial Services Healthcare Industrials Technology By Location Americas Asia Europe What We Do Mergers & Acquisitions Private Funds Advisory Capital Advisory & Restructuring Valuation … nion to Pantheon in connection with its inaugural private equity collateralized fund obligation, which closed at $1 billion Lincoln International advised Baird Capital on closing its continuation fund to fuel growth of Blue Matter Healthcare Lincoln International advised Reverence Capital Partners on the $2 billion recapitalization of Osaic Financial Services Lincoln International advised Alder II AB in divesting SI and SMG to Alder Strategic Opportunity Fund I Building Produ … ln International advised Boyne Capital on Closing its Single-Asset Continuation Fund for Pilot Energy Business Services Lincoln International has advised CirrusMD on its acquisition by Quantum Health Healthcare Lincoln International advised Ares on the closing of $850 Million Single-Asset Continuation Vehicle for Convergint Business Services View All Transactions Any information or testimonials contained in this post may not be representative of the experience of other client
%PDF-1.7 %���� 9 0 obj > stream x��]]��r}�_��"���!�X`fv�"Hrȳ��^ � ����CITK��#Ց(M�n{�����E��ԩb�M��w*�-F��J���p������E0�?}�u�\��I�`����TU]������������ ]���YS��ۭ�b����Ͽ�� �����Ŝ�� ʶ1!�mkW5��}V6/w?ė��|���O���__��S|�������� ~��~��� ~��ӟ������Z�O���Ω}�:���u���c[��P�pr���ߗei>���χ�}��~��Re���:>ʜ��`����)4c� H V�N��f����6é�m߭�7��2 �UW��K��kAX,���(5�jS�{S�2>�?t�0�++�~7Vԍ@���|��a�]?�n����~� ��?������ W���TO��+oI�u/aQx� 1�� Q�Qs.��T(�D� 1q ��6q6|*̄��(���u�t|����O�D����B�R�z��}EUe�7�7���JR/�؇�t����+ea���K��`'���o�~5;�Z�B٦+J�s�;������}ci�ntN�̌a��e 7���_��T�U��!l … d"����tC� ���~�q���m����Z/�֗�� �I�~b_vЃ�Z/����$Y��j+����r��+��K���k�e���RFP{���5��+J^�LT&[�d����"h�Z�Thy��4h����[6 �"Bk�$���b�L��W���I^] �o����� �>�|�����x�����a�&zּ9 _»�ɣ������3x������R������[����e˩�N�S�߃^���O���ׯnt�,Y�'cbl��ǥTg)���3�g�kN ���2'#�G�K��B2�:r�r� F��)�^���8K����Sׂd$B��� ސ��,eG�3�c�#gߑs;K,2}N&h�Lw��#�J��u���#�#2=B�d0h� ;Kّt%Cc�#'���� G�МL�� rn��#� ��Α�wP�2 > stream x���MoA ���>�)����^ ��"� q�h*�=�7Y4�v���l6������P,!@�O�\- �-b�B
Latham Watkins Advises BridgeBio Pharma in US1-25 Billion Cross-Border Funding skip to Main Content skip to Footer Toggle Menu Menu People Capabilities Achievements Insights Global Citizenship Search Toggle Search Bar Latham & Watkins LLP Local Language pages Global English Chinese 中文 French Français German Deutsch Italian Italiano Japanese 日本語 Korean 한국어 Spanish Español People Capabilities Achievements Insights Featured Insights Explore All Resources & Tools Book of Jargon Blogs Podcasts Webcasts Global Citizenship Overview Pro Bono & Community Service Inclusion, Opportunity & Com … iate Mitch Bennett*; on ERISA matters by partner Julie Crisp; and on investment fund regulatory matters by partner Laura Ferrell, with associate Jennifer Tian; and on security/intercreditor matters by counsel Emily Leong Yu. *Admitted to practice in New South Wales (Australia) only. Endnotes Show All Endnotes Collapse Endnotes Contacts Haim Zaltzman New York / San Francisco / Silicon Valley [email protected] Dan Van Fleet San Francisco / Silicon Valley [email protected]
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans. He describes the label and what he believes it means for… | BiotechTV LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM
BridgeBio Pharma Inc. - Financials - SEC Filings Skip to main content Overview Events & Presentations Stock Info Stock Quote Analyst Coverage Financials Quarterly Results Annual Reports SEC Filings Governance Governance Documents State Disclosures Board of Directors Committee Composition Resources Investor Email Alerts Contact Us SEC Filings Quarterly Results Annual Reports SEC Filings SEC Filings filter Options Select Year: Filing Type: All Form Types Annual Quarterly Current Report Proxy Registration Section 16 Other Date Filing Type Filing Description Download / View SEC Filings documents g
Eidos Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Eidos Therapeutics BridgeBio Pharma is a biopharmaceutical company dedicated to discovering, creating, testing, and delivering transformative medicines for patients suffering from genetic diseases. With a focus on genetic disorders and cancers with clear genetic drivers, BridgeBio aims to develop breakthrough therapies at an unprecedented scale by leveraging scientific advancements and a unique operating model that emphasizes speed, scale, and scientific rig
Careers | BridgeBio Oncology Therapeutics | Best-in-RAS About Pipeline Publications Investors Careers Contact Us Menu Menu Careers Join Our Team Transforming the Lives of Patients We are actively looking to fill these open positions See Open Positions Our Mission Our Values Put Patients First Move Boldly Swarm the Problem Own it End-to-End Be Radically Transparent Benefits We offer competitive benefits that value our employees’ physical, emotional, and mental health. Health and Wellness Medical, Dental, and Vision Insurance Supplemental Medical Insurance Lifestyle Spending Account with $100 mo … lexible PTO Minimum of 15 Paid Holidays (includes Year End Shutdown) Cell Phone Stipend Financial Success 401(k) Plan (with generous employer matching contribution) Life & AD&D, Short-and- Long-term Disability 100% paid for by BBOT Compensation Competitive Base Pay Bonus Opportunities Stock Options (Subject to Board Approval) Additional Benefits/Perks Flexible Work Arrangement Employee Recognition and Appreciation Subsidized In Office Lunches and unlimited snacks/dr … ity to work on future positions. Recruiters interested in working with BBOT can submit their information to [email protected] – should we have a tough-to-fill role, we will contact you directly if you specialize in that area. ©2026 BBOT. All Rights Reserved. | Privacy Policy | Terms of Use Scroll to top Scroll to top Scroll to top This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Accept settings Hide notification only Sett
ATTR-CM Condition Research & Scientific Insights – BridgeBio | BridgeBio skip to cookie settings skip to content BridgeBio Navigation About Science Pipeline Medicines Attruby® (acoramidis) ↗ NULIBRY® (fosdenopterin) ↗ Patients Insights News Careers Investors Research Research Clinical Trials Presentations and Publications Grants and Funding Conditions Conditions Achondroplasia → Achondroplasia What Is Achondroplasia? Clinical Trial Presentations & Publications Glossary ADH1 → ADH1 What Is ADH1? Clinical Trial ↗ Presentations & Publications Glossary ATTR-CM → ATTR-CM What is ATTR-CM